hormone, glucocorticoids and the catecholamines norepinephrine and epinephrine], additional mediators, such as nerve growth factor (NGF) and several cytokines, have been identified as important players of the stress response. Circulating NGF levels are increased in patients with inflammatory skin diseases, such as psoriasis [7] .
Mast cells are involved in the development of allergic and late-phase inflammation reactions [2] . They are also implicated in nonallergic inflammation, as they release several proinflammatory cytokines, such as tumor necrosis factor and other inflammatory mediators (Table 1) . Mast cells are located perivascularly in close proximity to peripheral neuron terminals, including both those of postganglionic sympathetic and sensory [dorsal root ganglia (DRG) neurons] neurons originating in the sympathetic and DRG, respectively (Fig. 1) . Skin mast cells produce CRH and express CRH receptors type 1 [4, 6] . They can be activated by many neuropeptides secreted by postganglionic sympathetic and sensory neurons, especially peripheral CRH, substance P (SP), and calcitonin gene-related peptide (CGRP), in response to stress, or by inflammatory mediators. Stress-induced or -aggravated neuroinflammatory skin conditions have been associated with mast cell activation and degranulation. Similarly, we have previously shown that stress induces intracranial mast cell activation, through the sequential action of CRH and sensory neuropeptides [9] , and that CRH degranulates skin mast cells and increases vascular permeability [8] .
In a murine model of stress involving exposure of C57BL/6 mice to sound stress, Joachim et al. [3] and CGRP + sensory neurons in skin-innervating DRG neurons, as well as on dermal sensory nerve fibers. This suggests that NGF plays a major role in the neurogenic component of inflammation and that it is a major mediator of the effects of stress in the skin.
No target-specific pharmacologic interventions are currently available for the management of stress-triggered oraggravated skin disorders. The findings by Joachim et al. [3] provide a useful model to conceptualize and generate more effective therapies for these disorders. Thus, abrogation of mast-cell activation, degranulation and local cytokine secretion by blockade of DRG neuron products appears to be a possible area of further investigation for the treatment of stress-related skin disorders. Another possible approach may be the inhibition of the principal stress regulator CRH and peripheral CRH by using CRH receptor type 1 antagonists, such as antalarmin [10] . This small molecular CRH antagonist was previously shown to block CRH-induced mast cell degranulation [9] . Finally, blockade of other stressrelated DRG neuron-produced and mast cell-regulating neuropeptides, such as SP, CGRP, or NGF, could be promising areas of research in this direction. Fig. 1 The stressed brain (CNS) exerts its effects on the skin through the stress and sensory afferent systems through endocrine and neural pathways. The first includes effects of the circulating hormones of the HPA axis and sympathetic system, respectively, cortisol (F, corticosterone in rodents) and the catecholamines norepinephrine (NE) and epinephrine (E) on skin cells including mast cells and other immunocytes. The stress system also influences skin targets through the terminals of the postganglionic neurons (PGN) emanating from the sympathetic ganglia secreting norepinephrine and a variety of other mediators, including several neuropeptides, such as CRH. The sensory afferent system influences the skin through peripheral nerve fibers emanating from the dorsal root ganglia (DRG), also secreting a variety of mediators such as substance P (SP)
The results reported by Joachim et al. may shed light on the pathophysiology of neuroimmune skin disorders, which are clearly triggered or exacerbated by stress and provide a tool to investigate new treatment strategies for the management of such disorders.
